Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia

Blood

Volumn 87, Issue 5, 1996, Pages 1962-1971

  Bosanquet, Andrew G ^a,b   Bell, Philip B ^a  

^a UNIVERSITY OF BATH   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; MAFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; MITOMYCIN C; MITOXANTRONE; PREDNISOLONE; STEROID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030029580     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.5.1962.1962     Document Type: Article

References (44)

1. Juliano RL, Ling VA: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152, 1976
2. Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, Hofmann J, Thaler J: Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 85:1751, 1993
3. Sparrow RL, Hall FJ, Siregar H, Van der Weyden MB: Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 17:941, 1993
4. Nooter K, Sonneveld P: Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res 18:233, 1994
5. Wulf O, Kluding H, Ho AD, Doerner M, Doehner H, Manegold C, Hunstein W: Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and Northern blot analysis. Leuk Res 18:475, 1994
6. Burger H, Nooter K, Zaman GJR, Sonneveld P, Van Wingerden KE, Oostrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8:990, 1994
7. Burger H, Nooter K, Sonneveld P, Van Wingerden KE, Zaman GJR, Stoter G: High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 88:348, 1994
8. Reeve JG, Rabbitts PH, Twentyman PR: Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line. Br J Cancer 61:851, 1990
9. Gruber A, Larsson R, Nygren P, Björkholm M, Peterson C: A non-P-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells. Leukemia 8:985, 1994
10. Johnston JB, Israels LG, Goldenberg GJ, Anhalt CD, Verburg L, Mowat MRA, Begleiter A: Glutathione S-transferase activity, sulfhydryl group and glutathione levels, and DNA cross-linking activity with chlorambucil in chronic lymphocytic leukemia. J Natl Cancer Inst 82:776, 1990
11. Schisselbauer JC, Silber R, Papadopoulos E, Abrams K, LaCreta FP, Tew KD: Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res 50:3562, 1990
12. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313, 1994
13. Hochhauser D, Harris AL: The role of topoisomerase IIα and β in drug resistance. Cancer Treat Rev 19:181, 1993
14. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83:517, 1994
15. Saijo N, Lazo JS: Metallothioneins in drug resistance, in Teicher BA (ed): Drug Resistance in Oncology. New York, NY, Marcel Dekker, 1993, p 339
16. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
17. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW: TCA-100 Tumor chemosensitivity assay: Differences in sensitivity between cultured tumor cell lines and clinical studies. J Biolumin Chemilumin 9:373, 1994
18. Su GMI, Davey MW, Davey RA, Kidman AD: Development of multidrug resistance in HL60 promyelocytic leukaemia cells. Br J Haematol 88:566, 1994
19. Bosanquet AG, Bell PB: Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk Res 20:143, 1996
20. Gale RP, Foon KA: Chronic lymphocytic leukemia. Ann Intern Med 103:101, 1985
21. Tietjen GL: A Topical Dictionary of Statistics. London, UK. Chapman & Hall, 1986, p 14
22. Bosanquet AG, Amos AS, Bell PB, Burlton AR, Greaves MF: Comparison of BCL-2 and MDR-1 levels with in vitro drug sensitivities by DiSC assay in B-cell and other malignancies. Br J Haematol 87:83, 1994 (suppl 1)
23. Woolley PV, Tew KD (eds): Mechanisms of Drug Resistance in Neoplastic Cells. San Diego, CA, Academic, 1988
24. Begleiter A, Goldenberg GJ, Anhalt CD, Lee K, Mowat MRA, Israels LG, Johnston JB: Mechanisms of resistance to chlorambucil in chronic lymphocytic leukemia. Leuk Res 15:1019, 1991
25. Weisenthal LM, Nagourney RA, Kern DH, Boullier B, Bosanquet AG, Dill PL, Messenger JC, Moran EM: Approach to clinical circumvention of drug resistance utilising a non-clonogenic in vitro assay measuring the effects of drugs, radiation and interleukin II on largely non-dividing cells. Adv Clin Oncol 1:91, 1989
26. Mughal TI, Goldman JM: Chronic leukaemias: Can they be cured? Part II: Chronic lymphocytic leukaemia. Br J Clin Pract 43:353, 1989
27. Cheson BD: Therapy for chronic B-cell leukaemias. Recent Adv Haematol 6:107, 1992
28. Lenormand B, Bizet M, Fruchart C, Tilly H, Daliphard S, Thouret F, Canipel C, Callat MP, Piguet H, Lefranc MP, Monconduit M: Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia 8:1019, 1994
29. Richardson DS, Johnson SA, Hopkins JA, Howe D, Phillips MJ: Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine. Acta Oncol 33:627, 1994
30. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D: Methylprednisolone in advanced chronic lymphocytic leukaemia: Rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 93:73, 1995
31. Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk I, Klumper E, Hählen K, de Waal FC, van Wering ER: In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 8:24, 1994
32. Juliusson G, Elmhorn-Rosenborg A, Liliemark J: Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327:1056, 1992
33. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M: Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 330:319, 1994
34. Sawitsky A, Rai KR, Glidewell O, Silver RT, and participating members of CALGB (Cancer and Leukemia Group B): Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50:1049, 1977
35. Young RC: Mechanisms to improve chemotherapy effectiveness. Cancer 65:815, 1990 (suppl)
36. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, Van Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/ MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1:81, 1995
37. Borst P, Schinkel AH, Smit JJM, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EWHM, Baas F, Zaman GJR. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60:289, 1993
38. Weisenthal LM: Predictive assays for drug and radiation resistance, in Masters JRW (ed): Human Cancer in Primary Culture. Dordrecht, The Netherlands, Kluwer Academic, 1991, p 103
39. Fruehauf JP, Bosanquet AG: In vitro determination of drug response: A discussion of clinical applications. Principles & Practice of Oncology Updates 7 (December):1, 1993
40. Bosanquet AG: Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test result with both patient response and survival. Forum Trends Exp Clin Med 4:179, 1994
41. Larsson R, Nygren P: Laboratory prediction of clinical chemotherapeutic drug resistance: A working model exemplified by acute leukaemia. Eur J Cancer 29A:1208, 1993
42. Bosanquet AG: The DiSC assay - 10 years and 2000 tests further on, in Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (eds): Drug Resistance in Leukemia and Lymphoma. The Clinical Value of Laboratory Studies. London, UK, Harwood, 1993, p 373
43. Bosanquet AG: In vitro drug sensitivity testing for the individual patient: An ideal adjunct to current methods of treatment choice. Clin Oncol 5:195, 1993
44. O'Brien S, del Giglio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85:307, 1995